Afamelanotide Completed Phase 2 Trials for Protoporphyria, Erythropoietic Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01097044Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)